The present invention refers to a pharmaceutical formulation for injection comprising fluorescent nanoparticles as in vivo diagnostics. The present invention relates to an injectable pharmaceutical formulation for human medicine and/or veterinary use, comprising 17% to 20% per weight of poloxamer 407 and 3%-15% per weight of poloxamer 188, 0.10 nM to 10.0 μM fluorescent nanoparticles and water or an aqueous buffer, wherein the pharmaceutical formulation is liquid at 4° C.-32° C. and forms a gel at about 37° C., their use as an in vivo marker and methods of their preparation. The inventive formulation is useful for local control and prevention of spreading/diffusion of nanoparticles, and thus allows full utilization of their quantum physics properties for example as a tool to enable surgical precision of tumor removal; even without tumor specific epitope binding antibodies.

This disclosure relates to nanoparticles carrying nucleic acid cassettes for expressing RNA. In certain embodiments, the disclosure relates to improved methods for targeted delivery and expression of siRNAs in vivo using DNA-based siRNA-expressing nanocassettes and receptor-targeted nanoparticles. In certain embodiments, the disclosure relates to methods of targeted delivery of survivin siRNA expressing nanocassettes which enhance sensitivity of human cancer cells to anticancer agents.

A nanophosphor in accordance with one exemplary embodiment of the present disclosure includes a fluoride-based nanoparticle co-doped with Ce.sup.3+ and one selected from a group consisting of Tb.sup.3+, Eu.sup.3+ and a combination thereof. The nanophosphor may be excited by a single wavelength of ultraviolet rays to emit various colors of green, yellow, orange, red and the like, and exhibit high photostability without photoblinking. The nanophosphor may be utilized as a bio imaging contrast agent, a transparent display device, an anti-counterfeit code and the like.

An imager for in vivo viewing of diseased tissue by way of fluorescently conjugated molecules. A generally planar imaging surface with a microlens array. The imager may be modular, such that a plurality of generally planar imaging surfaces can be used to image various aspects of disease tissue simultaneously. Certain implementations include an angle-selective imager, wherein light from substantially perpendicular to the plane of the imager is received, while incident light is selectively eliminated.

Nanoparticles containing a mitochondrial that are capable of crossing the blood-brain barrier and that have a targeting moiety, an antioxidant and an anti-inflammatory agent may be useful for treatment of traumatic brain injury.

In this invention, polyimidazole ligands (PILs) incorporating pendant imidazole moieties for nanocrystal binding and either sulfonatebetaine, carboxybetaine, or phosphocholinebetaine moieties for water-solubilization have been developed. Greatly enhanced stability of nanocrystals (both over time and in wide pH range) was achieved by incorporating multi-dentate imidazole moieties which provide strong coordination of the ligand to the nanocrystal surface and prevent aggregation of nanocrystals. Synthesis of betaine PILs was developed by modifying the synthesis of recently developed PEG containing poly imidazole ligands (PEG PILs). These nanocrystals are compact, water soluble, and biocompatible.

A bioluminescence energy transfer (BRET) nanosystem having semiconductive quantum rods (QRs) bound by firefly luciferase Photinus pyralis (Ppy) for improved conversion of chemical energy to light, such as in solid-state lighting, near-infrared imaging systems, and in vivo infrared imaging. The nanosystems are formed by synthesizing CdSe/CdS or CdSe/CdS/ZnS quantum rods, rendering the dots hydrophilic and colloidially stable with a facile His-capping, incubating with a Ppy variant (PpyGRTS) at increasing loading ratios, and adding an excess of the luciferin (LH2) substrate to the PpyGRTS-QRs.

A micro robot that is moveable in a body includes first quantum dots.

Protected quantum dots are protected from degradation, particularly in aqueous environments, The system comprises quantum dots, hydrophobic core, and hydrophilic shell. The quantum dots are entrapped in and protected by the hydrophobic core. The core polymer is covalently bonded to a hydrophilic shell polymer or protein. Quantum yield is better maintained than for non-encapsulated quantum dots in an aqueous environment. Optionally, ligands are attached to the hydrophilic shell to target delivery of the protected quantum dots, In an alternative embodiment, quantum dots are entrapped in the hydrophilic shell, or in both the shell and the core.

Provided are cubic-phase (α-phase) erbium (Er)-doped near-infrared-II (NIR-II)-emitting nanoparticles. In certain embodiments, the nanoparticles are near-infrared-IIb (NIR-IIb)-emitting nanoparticles. Also provided are nanoparticles having disposed thereon a layer-by-layer crosslinked polymeric hydrophilic biocompatible coating. Also provided are compositions comprising the nanoparticles of the present disclosure. Methods of using the nanoparticles, e.g., for in vivo imaging, are also provided.